Back to Browse Journals » Neuropsychiatric Disease and Treatment » Volume 2 » Issue 3

Religiosity in patients with Parkinson's disease

Authors Patrick McNamara, Raymon Durso, Ariel Brown

Published Date October 2006 Volume 2006:2(3) Pages 341—348

DOI http://dx.doi.org/

Published 10 October 2006

Patrick McNamara, Raymon Durso, Ariel Brown

Department of Neurology, Boston University School of Medicine, Boston, MA, and VA Boston Healthcare System, Boston, MA, USA

Objective: To study clinical correlates of religiosity in Parkinson’s disease (PD).

Methods: Measures of life goals, religiosity, mood, and neuropsychologic function were assessed in 22 persons with mid-stage PD and 20 age-matched healthy controls. Levodopa dose equivalents (LDE) were also computed for the patients.

Results: Relative to other major life goals parkinsonian patients were significantly more likely to report that “my religion or life philosophy” was less important than were age-matched controls. Scores on a battery of religiosity scales were consistently lower for Parkinson’s patients than those of age-matched controls. While Mini Mental State Exam, logical memory recall, Stroop, and selected (depression and anxiety) mood scales reliably distinguished patients from controls, only measures of prefrontal function correlated with religiosity scores.

Conclusions: Patients with PD express less interest in religion and report consistently lower scores on measures of religiosity than age-matched controls. Prefrontal dopaminergic networks may support motivational aspects of religiosity.

Keywords: religiosity, Parkinson’s disease, neuropsychology, mood, executive functions, dopamine agonists

Download Article [PDF] 

Readers of this article also read:

Effects of irbesartan on serum uric acid levels in patients with hypertension and diabetes

Nakamura M, Sasai N, Hisatome I, Ichida K

Clinical Pharmacology: Advances and Applications 2014, 6:79-86

Published Date: 3 May 2014

Pharmacokinetics and pharmacodynamics of acetylsalicylic acid after intravenous and oral administration to healthy volunteers

Nagelschmitz J, Blunck M, Kraetzschmar J, Ludwig M, Wensing G, Hohlfeld T

Clinical Pharmacology: Advances and Applications 2014, 6:51-59

Published Date: 19 March 2014

Population pharmacokinetics of olprinone in healthy male volunteers

Kunisawa T, Kasai H, Suda M, Yoshimura M, Sugawara A, Izumi Y, Iida T, Kurosawa A, Iwasaki H

Clinical Pharmacology: Advances and Applications 2014, 6:43-50

Published Date: 4 March 2014

Detemir as a once-daily basal insulin in type 2 diabetes

Nelson SE

Clinical Pharmacology: Advances and Applications 2011, 3:27-37

Published Date: 18 August 2011

Long-term treatment of bipolar disorder with a radioelectric asymmetric conveyor

Mannu P, Rinaldi S, Fontani V, Castagna A

Neuropsychiatric Disease and Treatment 2011, 7:373-379

Published Date: 15 June 2011

Bone resorption in incompletely impacted mandibular third molars and acute pericoronitis

Minoru Yamaoka, Yusuke Ono, Masahiro Takahashi, Ryosuke Doto, et al.

Clinical, Cosmetic and Investigational Dentistry 2009, 1:7-12

Published Date: 14 April 2009

Applications of gold nanoparticles in cancer nanotechnology

Weibo Cai, Ting Gao, Hao Hong, Jiangtao Sun

Nanotechnology, Science and Applications 2008, 1:17-32

Published Date: 19 September 2008